Therapeutics

LU AF82422

Overview

Name: LU AF82422
Therapy Type: Immunotherapy (passive) (timeline)
Target Type: alpha-synuclein
Condition(s): Parkinson's Disease
U.S. FDA Status: Parkinson's Disease (Phase 1)
Company: Genmab A/S, H. Lundbeck

Background

LU AF82422 is a humanized monoclonal IgG1 antibody targeting the C-terminal of α-synuclein. Genetic and pathology evidence implicate aggregated forms of this protein in the molecular pathogenesis of Parkinson’s disease and other α-synucleinopathies such as dementia with Lewy bodies (DLB).

No preclinical data on this antibody have been published.

LU AF82422 is one of several α-synuclein antibodies being investigated for PD. Others include ABBV-0805BIIB054MEDI1341, and prasinezumab.

Findings

Lundbeck began a Phase 1 safety study of LU AF82422 in July 2018. The study is to enroll 60 healthy Japanese and non-Japanese volunteers and 24 people with Parkinson’s disease at four sites in the United States. Participants will receive one of three doses of antibody or placebo by infusion, followed by 12 weeks of observation.  The trial will also measure exposure and pharmacokinetics of the antibody in blood. Completion is anticipated in December 2020.

For details on LU AF82422 trials, see clinicaltrials.gov.

Last Updated: 16 Jul 2020

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Therapeutics Citations

  1. ABBV-0805
  2. MEDI1341
  3. Prasinezumab

Other Citations

  1. BIIB054

External Citations

  1. clinicaltrials.gov

Further Reading

No Available Further Reading